Clinical Trials on Dyslipidemia, Renal Insufficiency

Total 16359 results

GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
AstraZeneca

Completed

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Dyslipidemia, Renal Insufficiency

United States
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
Amgen

Completed

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Hyperlipidemia | Mixed Dyslipidemia

United States
National and Kapodistrian University of Athens

Completed

Dyslipidemia-related Risk Factors in Dialysis

Cardiovascular Disease | Dyslipidemia | Chronic Renal Disease
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Dyslipidemia
AstraZeneca

Completed

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Dyslipidemia | Kidney Disease

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Chronic Kidney Disease

Belarus, Bulgaria, Romania, Malaysia, Singapore, Thailand, Italy, Lithuania, Latvia, Croatia, Denmark, Israel, Indonesia
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
Mitsubishi Tanabe Pharma Corporation

Completed

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Dyslipidemia | Chronic Kidney Disease | Hyperphosphatemia | Dialysis

Poland, Ukraine, Serbia, Russian Federation, Hungary, Malaysia, Italy, Macedonia, The Former Yugoslav Republic of
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
Assiut University

Unknown

Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases

CKD
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
AstraZeneca

Completed

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Fredrickson Type IIa & Type IIb Dyslipidaemia
University of Ioannina
University Hospital, Ioannina

Completed

The Effect of Childhood Dyslipidemia on Endothelial and Renal Function

Dyslipidemias | Endothelial Dysfunction | Children, Only | Renal Dysfunction | Hypercholesteremia in Children

Greece
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR)

Completed

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Insulin Resistance | Dyslipidaemia

Canada
GlaxoSmithKline

Completed

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

Obesity | Hypercholesterolemia | Dyslipidaemias

United States
GlaxoSmithKline

Terminated

Effect Of GW501516X On How The Heart Obtains And Uses Energy

Heart Failure | Dyslipidaemias

United States
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Dyslipidemia
Mayo Clinic

Completed

Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure

Hypertension | Hyperlipidemia | Chronic Renal Failure
Genfit

Completed

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Abdominal Obesity | Atherogenic Dyslipidaemia

France, Romania, Tunisia
Yonsei University

Not yet recruiting

Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease (EXCELSIOR-CKD)

Hypertension | Chronic Kidney Diseases | Dyslipidemias

Korea, Republic of
Hanlim Pharm. Co., Ltd.

Recruiting

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap

Mixed Dyslipidemia

Korea, Republic of
IlDong Pharmaceutical Co Ltd

Not yet recruiting

A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

Mixed Dyslipidemia
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

Mixed Dyslipidemia

United States, Australia, Poland, New Zealand, Canada, Hungary
Provident Clinical Research
Reliant Pharmaceuticals

Completed

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia
The Hospital for Sick Children

Completed

Omega-3 Fatty Acid Supplementation in Children

Chronic Kidney Disease | Hypertriglyceridemia

Canada
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)

Mixed Dyslipidemia

United States, Australia, Canada, New Zealand
Yooyoung Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

Combined Dyslipidemia

Korea, Republic of
Société des Produits Nestlé (SPN)

Completed

Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (Lipidown)

Primary Dyslipidemia

China
Provident Clinical Research
Reliant Pharmaceuticals

Unknown

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Mixed Dyslipidemia
Kowa Research Institute, Inc.

Completed

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (PREVAIL-US)

Mixed Dyslipidemia | Primary Dyslipidemia

United States

3

Subscribe